Spesolimab: First Approval
Hannah A. Blair
Abstract
) is an interleukin (IL)-36 receptor antagonist being developed by Boehringer Ingelheim for the treatment of various immune-mediated disorders. In September 2022, spesolimab was approved in the USA for the treatment of generalized pustular psoriasis (GPP) flares in adults. This article summarizes the milestones in the development of spesolimab leading to this first approval for GPP flares.
Topics & Concepts
MedicinePsoriasisDrug approvalInterleukin 1 receptor antagonistPharmacologyAntagonistDermatologyReceptor antagonistInternal medicineDrugReceptorPsoriasis: Treatment and PathogenesisAsthma and respiratory diseasesDermatology and Skin Diseases